Advertise on podcast: Gynecologic Oncology Update

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00)Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29) CME information and select publications

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00)Ovarian Cancer (2:22)Endometrial Cancer (37:48) CME information and select publications

Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00)Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31)Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02)Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25)Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43)Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic: Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann CME information and select publications

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics: Introduction (0:00)Preventing Ovarian Cancer (1:04)Endometrial Cancer (5:27)Ovarian Cancer (25:36)Cervical Cancer (54:04) CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49) CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)Current and future role of avutometinib with defactinib for LGSOC (19:23)A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37) CME information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03) CME information and select publications

Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)Current and investigational targets of ADCs in gynecologic cancers (17:14)Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (00:00)Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41) CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00)Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications